Stiripentol vs add‐on placebo: Neurological adverse effects
Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Add‐on stiripentol vs add‐on placebo Neurological adverse effects · people with drug‐resistant focal epilepsy Add‐on stiripentol showed no clear difference in neurological adverse effects compared with add‐on placebo (low certainty). Stiripentol add‐on therapy for drug‐resistant focal epilepsy (2022) · Cochrane Headline outcomes only | RR 2.65 [0.88, 8.01] | 1 study · 32 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Stiripentol add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.